Articles By Anuja Singh
Will Sanofi’s $9.5B Acquisition of Blueprint Redefine the Future of Rare Immunology?
Key Takeaways for Biopharma Executives Strategic Expansion: Sanofi Bets Big on Rare Immunology and US Biotech InnovationIn a…
By
Can Bristol Myers Squibb and BioNTech’s $1.5B Bet on Bispecific Antibodies Disrupt PD1-VEGF Cancer…
Key Takeaways for Industry Leaders Strategic Shift: BMS Moves Deeper into Bispecific Immuno-OncologyIn a bold move signaling growing…
How GSK-Backed Onc.AI Is Using Deep Learning Radiomics to Disrupt Imaging Biomarkers in Biopharma…
Key Highlights: Reinventing RECIST: How Onc.AI’s Serial CTRS is Transforming Imaging BiomarkersOnc.AI is redefining how oncology imaging data…
How Massive Bio’s AI is Unlocking Global Oncology Access for 3,800+ Cancer Patients Through…
Key Highlights: Revolutionizing Cancer Care With Multi-Agent AI at ASCO25Massive Bio is presenting its cutting-edge AI technology at…
How 4D Molecular Therapeutics’ Innovative Gene Therapy Engine Is Revolutionizing Treatment for Retinal and…
Key Highlights: 1. Accelerated Clinical Milestones for 4D-150 in Wet AMD and DME: 4DMT initiated its first global…
Can BigHat and Lilly’s AI-Driven Antibody Partnership Redefine the Future of Biologics? A Two-Program…
Key Insights AI-Driven Discovery: BigHat’s Milliner™ Platform Sets New StandardsAt the core of this collaboration is BigHat’s proprietary…
Will Sanofi’s $9.5B Acquisition of Blueprint Redefine the Future of Rare Immunology?
Key Takeaways for Biopharma Executives Strategic Expansion: Sanofi Bets Big on Rare Immunology and US Biotech InnovationIn a…
Can Bristol Myers Squibb and BioNTech’s $1.5B Bet on Bispecific Antibodies Disrupt PD1-VEGF Cancer…
Key Takeaways for Industry Leaders Strategic Shift: BMS Moves Deeper into Bispecific Immuno-OncologyIn a bold move signaling growing…
How GSK-Backed Onc.AI Is Using Deep Learning Radiomics to Disrupt Imaging Biomarkers in Biopharma…
Key Highlights: Reinventing RECIST: How Onc.AI’s Serial CTRS is Transforming Imaging BiomarkersOnc.AI is redefining how oncology imaging data…
How Massive Bio’s AI is Unlocking Global Oncology Access for 3,800+ Cancer Patients Through…
Key Highlights: Revolutionizing Cancer Care With Multi-Agent AI at ASCO25Massive Bio is presenting its cutting-edge AI technology at…
How 4D Molecular Therapeutics’ Innovative Gene Therapy Engine Is Revolutionizing Treatment for Retinal and…
Key Highlights: 1. Accelerated Clinical Milestones for 4D-150 in Wet AMD and DME: 4DMT initiated its first global…
Can BigHat and Lilly’s AI-Driven Antibody Partnership Redefine the Future of Biologics? A Two-Program…
Key Insights AI-Driven Discovery: BigHat’s Milliner™ Platform Sets New StandardsAt the core of this collaboration is BigHat’s proprietary…